Cell 70 , 136149.e137 (2018)
Studying gastrointestinal protection, gastric or hepatic ischemia, or general cytoprotection
In April 2024, the pharma company reported the topline results of a trial that found that people with obesity and sleep apnea who took tirzepatide (brand name Zepbound) for a year lost an average of 20% of their body weight and experienced a far larger reduction in apnea-related events at night than people taking a placebo
J., Draper, N., Lavery, G
Complex models such as LightGBM and artificial neural network all performed similarly to logistic regression
The genetic test identifies whether you carry variants associated with impaired satiety signaling, reduced GLP-1 receptor sensitivity, or fat mass dysregulation